人用狂犬病疫苗皮内接种的免疫原性与效果综述
本文综述1997-2018年公开发表数据,评估皮内接种狂犬病疫苗的免疫原性与效果。共纳入40篇免疫原性文献和13篇效果文献,发现皮内接种总体具有免疫原性,暴露后预防至少不劣于肌内接种,暴露前预防抗体滴度趋势偏低但无临床相关性,超3万例暴露后就诊数据未提示皮内接种缺乏效果。
要点
- 皮内接种狂犬病疫苗总体具有免疫原性,暴露后预防至少与肌内方案相当。
- 暴露前皮内接种抗体滴度趋势低于肌内接种,但未显示临床相关性。
- 超3万例暴露后预防数据未提示皮内接种疫苗缺乏效果。
核心结论
- 皮内接种狂犬病疫苗具有免疫原性,暴露后预防至少与肌内方案相当,暴露前抗体滴度趋势偏低但无临床相关性。
- 超过3万例暴露后预防就诊数据未提示皮内接种现行疫苗缺乏效果,支持现行皮内接种推荐。
研究设计与样本
- 文献综述:第一次检索1997-2018年免疫原性相关文献338篇,纳入40篇分析。
- 第二次检索2007-2018年效果相关文献371篇,保留13篇合适文献。
主要发现
- 皮内接种后达到0.5 IU/ml抗体阈值的受试者比例、疫苗效力与免疫原性关系、以及肌内与皮内抗体应答比较三方面分析显示皮内接种具有免疫原性。
- 暴露后预防皮内途径至少与肌内方案一样具有免疫原性。
- 暴露前预防皮内接种抗体滴度趋势低于肌内接种,但该观察无临床相关性。
- 超过3万例寻求狂犬病暴露后预防的患者数据未提示皮内接种现行疫苗缺乏效果。
关键数值与推荐
- 抗体阈值:0.5 IU/ml。
- 免疫原性分析纳入40篇文献(1997-2018年检索338篇)。
- 效果分析纳入13篇文献(2007-2018年检索371篇)。
临床怎么用
- 当前证据支持皮内接种狂犬病疫苗用于暴露前和暴露后预防的现行推荐。
- 皮内接种暴露前预防抗体滴度可能低于肌内接种,但未显示临床相关性。
局限性
- 已发表的皮内接种性能数据存在显著弱点,未来研究应更好地解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre- as well as post-exposure prophylaxis plays an important role in controlling the number of deaths associated with human rabies. Rabies vaccines, classically injected intramuscularly, are now also administered by intradermal (ID) route. Vaccines to be administered by the ID route should meet the same quality, safety and efficacy specifications as vaccines for intramuscular (IM) use. The aim of this paper is to provide information based on publicly available data regarding the ID use of rabies vaccines and to identify potential needs for further analysis of the potency, immunogenicity and effectiveness of rabies vaccines administered by this route. A first literature search, focused on the immunogenicity of rabies vaccines given by ID route, identified 338 publications in the period 1997-2018, 40 of which were included in our analyses. A second search investigating the effectiveness of ID vaccination resulted in 371 hits for the period 2007-2018, of which 13 suitable publications were retained. The immunogenicity of current rabies vaccines was analyzed in 3 ways: proportion of subjects reaching the antibody threshold of 0.5 IU/ml after ID vaccination, relationship between potency and immunogenicity of the vaccine given intradermally, and comparison of antibody responses after IM or ID vaccination. Overall, vaccines administered intradermally were found immunogenic. Post-exposure prophylaxis by ID route appeared at least as immunogenic as by IM regimens. By contrast, ID pre-exposure prophylaxis trended towards lower antibody titers than IM vaccination, but the observation was not associated with any clinical relevance. Vaccine effectiveness was assessed by investigating survival after exposure. Data from more than 30,000 patients who sought rabies post-exposure prophylaxis did not indicate that current vaccines administered by ID route lack efficacy. These results support current recommendations for ID vaccination against rabies. However, published data on ID performance were associated with significant weaknesses that future research should better address.
引用
- Denis M, Knezevic I, Wilde H, et al. An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route. Vaccine. 2018. PMID: 30551985. doi:10.1016/j.vaccine.2018.11.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。